{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222768","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-05-14T11:15:16+00:00","discovered_at":"2026-05-14T11:20:00.334965+00:00","generated_at":"2026-05-14T11:21:06.247242+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"REGENXBIO RGX-202 Phase III meets primary endpoint (p<0.0001); Q1 net loss $90.1M","bullets":["Primary endpoint achieved: 93% of patients >10% microdystrophin expression at Week 12 (p<0.0001); average expression 71.1%.","Significant correlation between microdystrophin expression and functional improvement (NSAA, p=0.0002); supports surrogate endpoint for accelerated approval.","Q1 2026 net loss $90.1M ($1.72/share) vs prior-year net income $6.1M; revenue fell to $6.4M from $89.0M (prior year milestone).","Cash $150.5M at March 31 (vs $240.9M Dec 31); runway into early 2027; expects $100M AbbVie milestone upon first DR patient dosed in Q2 2026.","FDA lifted clinical hold on RGX-121; company preparing for RGX-202 BLA submission targeting potential accelerated approval in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222768","json":"https://secwatch.observer/filing/0001193125-26-222768.json","markdown":"https://secwatch.observer/filing/0001193125-26-222768.md","text":"https://secwatch.observer/filing/0001193125-26-222768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/0001193125-26-222768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:21:06.247242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}